Comparison On The Detection Of High-Risk HPV With The Technique Of Hybrid Capture 2 And Multiplex Fluorescent PCR For Oropharyngeal Cancer

Objective:This study is aimed to compare the performance hybrid capture 2(HC2)and multiplex fluorescent polymerase chain reaction(PCR)on the high-risk HPV for oropharyngeal cancer,thereby determine the feasibility of HC2 in detecting high-risk HPV.Methods:From January 2015 to September 2016,thrity-one patients with oropharyngeal squamous cell carcinoma were recruited from the Affiliated Hospital of Qingdao University.The diagnosis of oropharyngeal squamous cell carcinoma was confirmed pathologically.The infection rate of high-risk HPV in patients was detected using both HC2 and multiplex fluorescent PCR.Analyses were performed using SPSS17.0software.Concordance between the results of assays was tested using the kappa coefficient.The value of Kappa index value between 0.4 and 0.75 was interpreted as good conformability,while value greater than 0.75 was considered as very good conformability.Results:Positive results of high-risk HPV in HC2 were shown in 7 of 31 samples(22.58%),one of which was identified as negativity using multiplex fluorescent PCR detection.Positivity of high-risk HPV for multiplex fluorescent PCR was shown in 8of 31 samples(25.81%),two of which was determined as negative results using HC2 detection.In 6 samples(19.35%),HC2 and multiplex fluorescent PCR revealed concordant positive results.In another 22 samples(70.97%),HC2 and multiplex fluorescent PCR showed consistent negative results.HC2 and multiplex fluorescent PCR showed better consistency on the detection of high-risk HPV,the total coincidence rate being 90.32%,and the total consistency index(Kappa index)being0.7364.Conclusion:Our data showed that HC2 can be used for detecting multi high-risk HPV subtypes simultaneously,providing excellent concordance with multiplex fluorescent PCR.It is feasible to use HC2 technique for high-risk HPV detection in patients with oropharyngeal cancer,which might be an option for HPV DNA screening in these patients clinically with a prerequisite of strict quality management.